Clinical trial · Interventional
Insulin Sensitivity After Breast Cancer
Study of Molecular Causes of Metabolic Disorders in Obese Premenopausal Women After Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Epidemiological studies have revealed that 60-80% of women with breast cancer (BC) develop metabolic disorders that are similar to those observed in conditions like type 2 diabetes. These metabolic disorders, including insulin resistance, obesity, hyperinsulinemia, and glucose intolerance, are associated with increased BC recurrence and mortality. Skeletal muscle is the major site of glucose uptake in humans. The aims of the present project are to 1) determine the involvement of insulin resistance in skeletal muscle in the metabolic disorders prevalent in BC survivors, 2) identify BC-and/or treatment-induced molecular changes in skeletal muscle from BC survivors .
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Insulin Sensitivity/Resistance | — | UNRESOLVED | — |
| Metabolic Disturbance | — | UNRESOLVED | — |
| Survivorship | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Insulin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Healthy control subjects
- description
- Healthy control subjects undergoing a hyperinsulinemic euglycemic clamp
- interventionNames
- Drug: Insulin
- type
- EXPERIMENTAL
- label
- Breast cancer survivors
- description
- Breast cancer survivors undergoing a hyperinsulinemic euglycemic clamp
- interventionNames
- Drug: Insulin
Primary outcomes (2)
- measure
- Insulin sensitivity status
- timeFrame
- 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * Premenopausal women operated for breast cancer and after completing adjuvant chemotherapy and no earlier than 3 weeks after its termination * BMI: 25-30 * Healthy controls will be included matched by gender, weight, age, and level of physical activity to the patient group included as subjects Exclusion Criteria: * Known postmenopause occurred at the time of diagnosis of breast cancer * Alcohol intake of\> 7 items / week * Smoker * Already known Type 2 diabetes mellitus or metabolic syndrome and medical treatment thereof. * Cardiovascular disease and its medical treatment * Impaired mobility
References
Publications (0)
Data not yet available